Long-acting Muscarinic Receptor Antagonists for the Treatment of Chronic Airway Diseases

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2014 Mar 4

PMID 24587893

Citations 35

Authors

Khuder Alagha

Alain Palot

Tunde Sofalvi

Laurie Pahus

Marion Gouitaa

Celine Tummino

Stephanie Martinez

Denis Charpin

Arnaud Bourdin

Pascal Chanez

Affiliations

Soon will be listed here.

Abstract

Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion. It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells. Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors. Three long-acting muscarinic receptor antagonists (LAMAs) were approved for the treatment of chronic obstructive pulmonary disease (COPD) in Europe: once-daily tiotropium bromide; once-daily glycopyrronium bromide; and twice-daily aclidinium bromide. All have higher selectivity for M3 receptors than for M2 receptors, and dissociate more slowly from the M3 receptors than they do from the M2 receptors. Some LAMAs showed anti-inflammatory effects [inhibition of neutrophil chemotactic activity and migration of alveolar neutrophils, decrease of several cytokines in the bronchoalveolar lavage (BAL) including interleukin (IL)-6, tumor necrosis factor (TNF)-α and leukotriene (LT)B4] and antiremodeling effects (inhibition of mucus gland hypertrophy and decrease in MUC5AC-positive goblet cell number, decrease in MUC5AC overexpression). In the clinic, LAMAs showed a significant improvement of forced expiratory volume in 1 second (FEV1), quality of life, dyspnea and reduced the number of exacerbations in COPD and more recently in asthma. This review will focus on the three LAMAs approved in Europe in the treatment of chronic airway diseases.

Citing Articles

Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment.

Shah B, Singh B, Wang Y, Xie S, Wang C Mediators Inflamm. 2023; 2023:8840594.

PMID: 37457746 PMC: 10344637. DOI: 10.1155/2023/8840594.

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.

Fukuda N, Horita N, Kaneko A, Goto A, Kaneko T, Ota E Cochrane Database Syst Rev. 2023; 6:CD012066.

PMID: 37276335 PMC: 10241721. DOI: 10.1002/14651858.CD012066.pub3.

Effects of tiotropium on the risk of coronary heart disease in patients with COPD: a nationwide cohort study.

Shin J, Lee J Sci Rep. 2022; 12(1):16674.

PMID: 36198721 PMC: 9535029. DOI: 10.1038/s41598-022-21038-1.

Effects of 4-DAMP on allergic rhinitis in guinea pigs and its potential mechanism.

Huang Y, Long R, Tang Y, Li J, Meng L, Yang J Ann Transl Med. 2022; 10(14):774.

PMID: 35965822 PMC: 9372692. DOI: 10.21037/atm-22-2998.

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review.

Calzetta L, Ritondo B, Zappa M, Manzetti G, Perduno A, Shute J Eur Respir Rev. 2022; 31(164).

PMID: 35508331 PMC: 9488979. DOI: 10.1183/16000617.0196-2021.

References

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

Milara J, Serrano A, Peiro T, Gavalda A, Miralpeix M, Morcillo E . Aclidinium inhibits human lung fibroblast to myofibroblast transition. Thorax. 2011; 67(3):229-37. PMC: 3282044. DOI: 10.1136/thoraxjnl-2011-200376. View

Peters S, Kunselman S, Icitovic N, Moore W, Pascual R, Ameredes B . Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010; 363(18):1715-26. PMC: 3011177. DOI: 10.1056/NEJMoa1008770. View

Voynow J, Rubin B . Mucins, mucus, and sputum. Chest. 2009; 135(2):505-512. DOI: 10.1378/chest.08-0412. View

Koyama S, Rennard S, Robbins R . Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol. 1992; 262(4 Pt 1):L466-71. DOI: 10.1152/ajplung.1992.262.4.L466. View

Buhling F, Lieder N, Kuhlmann U, Waldburg N, Welte T . Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med. 2007; 101(11):2386-94. DOI: 10.1016/j.rmed.2007.06.009. View

Sato E, Koyama S, Okubo Y, Kubo K, Sekiguchi M . Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol. 1998; 274(6):L970-9. DOI: 10.1152/ajplung.1998.274.6.L970. View

Gosens R, Rieks D, Meurs H, Ninaber D, Rabe K, Nanninga J . Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. Eur Respir J. 2009; 34(6):1436-43. DOI: 10.1183/09031936.00045209. View

Kelly E, Jarjour N . Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med. 2002; 9(1):28-33. DOI: 10.1097/00063198-200301000-00005. View

10.

Imai K, Dalal S, Chen E, Downey R, Schulman L, GINSBURG M . Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med. 2001; 163(3 Pt 1):786-91. DOI: 10.1164/ajrccm.163.3.2001073. View

11.

Kerstjens H, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M . Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012; 367(13):1198-207. DOI: 10.1056/NEJMoa1208606. View

12.

Koyama S, Sato E, Nomura H, Kubo K, NAGAI S, Izumi T . Acetylcholine and substance P stimulate bronchial epithelial cells to release eosinophil chemotactic activity. J Appl Physiol (1985). 1998; 84(5):1528-34. DOI: 10.1152/jappl.1998.84.5.1528. View

13.

Rogers D . Motor control of airway goblet cells and glands. Respir Physiol. 2001; 125(1-2):129-44. DOI: 10.1016/s0034-5687(00)00209-7. View

14.

Schelfhout V, Ferrer P, Jansat J, Peris F, Garcia Gil E, Pauwels R . Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. Br J Clin Pharmacol. 2010; 69(5):458-64. PMC: 2856046. DOI: 10.1111/j.1365-2125.2010.03622.x. View

15.

Profita M, Bonanno A, Siena L, Ferraro M, Montalbano A, Pompeo F . Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur J Pharmacol. 2008; 582(1-3):145-53. DOI: 10.1016/j.ejphar.2007.12.029. View

16.

Chanez P, Burge P, Dahl R, Creemers J, Chuchalin A, Lamarca R . Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2009; 23(1):15-21. DOI: 10.1016/j.pupt.2009.08.001. View

17.

Skold C . Remodeling in asthma and COPD--differences and similarities. Clin Respir J. 2010; 4 Suppl 1:20-7. DOI: 10.1111/j.1752-699X.2010.00193.x. View

18.

Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S . Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003; 58(5):399-404. PMC: 1746668. DOI: 10.1136/thorax.58.5.399. View

19.

Sykes D, Dowling M, Charlton S . Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol. 2009; 76(3):543-51. DOI: 10.1124/mol.108.054452. View

20.

Kistemaker L, Oenema T, Meurs H, Gosens R . Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012; 91(21-22):1126-33. DOI: 10.1016/j.lfs.2012.02.021. View